Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Wednesday, 17'th Jun 2026
SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,7
Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?
11:56am, Wednesday, 17'th Jun 2026
CYTK has gained 18.4% YTD as Myqorzo's FDA approval, early launch momentum, and expanding market opportunities fuel investor interest.
Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
03:58am, Tuesday, 09'th Jun 2026
Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
07:30am, Monday, 08'th Jun 2026
Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 3, 2026 SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Cytoki
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?
12:36pm, Thursday, 04'th Jun 2026
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
07:30am, Monday, 01'st Jun 2026
European Launch Follows Strong U.S. Start SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first comme
Cytokinetics to Participate in June Investor Conferences
04:00pm, Wednesday, 27'th May 2026
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following in
Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript
03:47pm, Wednesday, 27'th May 2026
Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise
04:04pm, Friday, 22'nd May 2026
Cytokinetics NASDAQ: CYTK executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug's label, REMS pro
Cytokinetics to Hold Annual Meeting of Stockholders
04:00pm, Wednesday, 20'th May 2026
SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 27, 2026
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:00pm, Monday, 18'th May 2026
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2026 it granted stock options to purchase an aggregate of 20,807
Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)
07:30am, Thursday, 14'th May 2026
Third Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
04:00pm, Tuesday, 12'th May 2026
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in a fireside chat
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026
10:06am, Monday, 11'th May 2026
SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the presentation of new data reinforcing the clinical profile of MYQORZO® (afic
SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of an underwritten public offering of 11,338,028 shares of its commo
